Manufacturer
Janssen Ortho LLC
Contents
Tapentadol
Indication
Chronic pain, Neuropathic pain, Moderate to severe acute pain,
Instruction
May be taken with or without food.
Drug interaction
Increased risk of serotonin syndrome w/ other drugs that enhance monoaminergic neurotransmission (e.g. TCAs, triptans, SSRIs, serotonin and norepinephrine reuptake inhibitors). Enhanced sedative effect w/ benzodiazepines, barbiturates, antipsychotics, H1-antihistamines and other opioids. Increased potential for addiction w/ mixed μ-opioid agonists/antagonists (e.g. nalbuphine, pentazocine) or partial μ-opioid agonists (e.g. buprenorphine). Increased systemic exposure w/ strong inhibitors of UGT1A6, UGT1A9 and UGT2B7 isoenzymes. Decreased efficacy w/ strong enzyme inducers (e.g. rifampicin, phenobarbital). Potentially Fatal: Additive effect w/ MAOIs or w/in 2 wk after withdrawal.
Malaysia
